Head of an independent Junior Research Group in Targ...

“Research for a life without cancer" is our mission at the German Cancer Research Center. We investigate how cancer develops, identify cancer risk factors and look for new cancer prevention strategies. We develop new methods with which tumors can be diagnosed more precisely and cancer patients can be treated more successfully. Every contribution counts – whether in research, administration or infrastructure. This is what makes our daily work so meaningful and exciting.

For the next possible date the German Cancer Research Center (DKFZ) is seeking a Head of an independent Junior Research Group in Target Screening and Immunoreceptor Engineering for Immunotherapy at NCT WERA (site Würzburg).

Reference number: 2025-0128

The National Center for Tumor Diseases (NCT) is a long-term cooperation between the DKFZ, excellent partners in university medicine and other outstanding research partners at various locations in Germany. With a focus on innovative clinical trials, the NCT enables new developments from the laboratory to be tested clinically quickly and to the highest standards, thereby making better diagnostic and treatment options available to patients. Special emphasis will be placed on personalized oncology, patient participation as research partners, rapid and fair patient access to advances in cancer research, and the training of future generations of clinical cancer researchers. The NCT has been expanded for this purpose. There are four new NCT sites in addition to Heidelberg and Dresden: Berlin, SouthWest (Tübingen/Stuttgart-Ulm), WERA (Würzburg with partners Erlangen, Regensburg, and Augsburg), and West (Essen/Cologne).

The NCT WERA is being established in collaboration between the German Cancer Research Center (DKFZ) as an alliance of the four universities and university hospitals of Würzburg, Erlangen, Regensburg and Augsburg. The four WERA partners cover a healthcare area of around eight million residents.

APCT1_DE